Michael Elman, MD
Retina Specialist · Baltimore, MDNPI 1760421929
Payments from drug & device makers
Across 644 payments — averaging $472.51 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Genentech, Inc.$87K
- AstraZeneca$68K
- Novartis$62K
- Apellis Pharmaceuticals, Inc.$38K
- Notal Vision, Inc.$22K
- Genentech USA, Inc.$16K
- plus $12K from 14 others
Across 2 payments — averaging $443.42 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- F. Hoffmann-la Roche AG$887
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Genentech, Inc. | 6 | $87,130 |
| AstraZeneca | 4 | $67,727 |
| Novartis | 9 | $61,991 |
| Apellis Pharmaceuticals, Inc. | 18 | $37,895 |
| Notal Vision, Inc. | 483 | $21,733 |
| Genentech USA, Inc. | 46 | $15,901 |
| F. Hoffmann-la Roche AG | 1 | $3,762 |
| AbbVie(2 entities) | 34 | $3,755 |
| Carl Zeiss Meditec, Inc. | 2 | $2,305 |
| Boehringer Ingelheim Finland Ky | 6 | $1,104 |
| Regeneron Healthcare Solutions, Inc. | 15 | $329 |
| Alcon | 2 | $292 |
| Bausch & Lomb Americas Inc. | 4 | $79 |
| Coherus Oncology, Inc. | 3 | $72 |
| Biogen | 4 | $72 |
| Boehringer Ingelheim | 1 | $60 |
| Alimera Sciences, Inc. | 3 | $34 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 1 | $25 |
| Kala Pharmaceuticals, Inc. | 1 | $19 |
| Harrow Eye, LLC | 1 | $16 |
How this compares
$304,299 in reported general payments places this provider in the 90th percentile of 47 retina specialist providers in Maryland.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other retina specialist in Baltimore
- Sidney SchechetBaltimore$23K
- Lisa SchocketBaltimore$7K
- Heather TamezBaltimore$4K
- Sean KimBaltimore$3K
- Daniel BrillBaltimore$3K
- David DaoBaltimore$3K
- Christina AntonopoulosBaltimore$304
- Kenneth TaubenslagBaltimore$150
- Adam GerstenblithHagerstown$8.6M
- Michael LaiChevy Chase$1.6M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.